ADMA Biologics, Inc.
corporate_fare Company Profile
ADMA Biologics, Inc. (NASDAQ:ADMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ADMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ADMA spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- ADMA Q3 Revenue $141.1M, EPS $0.22; FY26 Revenue Guidance Reiterated, Earnings Outlook Raised
- ADMA Biologics Posts 22-Cent Q3 EPS
- ADMA Advances SG-001 to cGMP Production, Eyes $300–$500M Peak Revenue
- ADMA Biologics Q2 2026: ASCENIV Drives 69% Gross Margin, Aggressive Buybacks Continue Amid Securities Lawsuit
- ADMA Lawsuit Alleges Channel Stuffing, Undisclosed Related Party; Lead Plaintiff Deadline Set
Financial Snapshot
Short Interest & Short Volume
7.11 days to coverFINRA reported short interest of 18,035,119 shares in ADMA as of the October 30, 2026 settlement, a 7.6% decrease from the prior period — about 7.1 days to cover at its recent average daily volume. On November 20, 2026, 32.9% of ADMA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.